Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Selective Inhibition of Bicyclic Tetrapeptide Histone Deacetylase Inhibitor on HDAC4 and K562 Leukemia Cell

  • Li, Xiao-Hui (School of Life Science and Biotechnology, Dalian University of Technology) ;
  • Huang, Mei-Ling (School of Life Science and Biotechnology, Dalian University of Technology) ;
  • Wang, Shi-Miao (School of Life Science and Biotechnology, Dalian University of Technology) ;
  • Wang, Qing (School of Pharmaceutical Science and Technology, Dalian University of Technology)
  • Published : 2013.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Histone deacetylase (HDAC) inhibitors of cyclic peptide have been proved to be the most complex but the most stable and relative efficient inhibitors because of their large cap region. In this paper, a series of studies were carried out to evaluate the efficacy of synthetic bicyclic tetrapeptide inhibitors 1-5 containing hydroxamic acid referring molecular docking, anti-proliferation, morphology and apoptosis. Docking analysis, together with enzyme inhibitory results, verified the selective capability of inhibitor 4 to HDAC4, which might closely related to haematological tumorigenesis, with Phe227, Asp115, Pro32, His198 and Ser114 participating into hydrophobic interactions and Van der Waals force which was familiar with former study. Moreover, inhibitor 4 inhibited K562 cell line at the $IC_{50}$ value of 1.22 ${\mu}M$ which was 51-67 times more efficient than that for U937 and HL60 cell lines. Inhibitor 4 exhibited the cell cycle-arrested capability to leukemia at S phase or G2/M phase as well as apoptosis-induced ability in different degrees. Finally, we considered that bicyclic tetrapeptide inhibitors were promising inhibitors used in cancer treatment and inhibitor 4 could prevent K562 cell line well from proliferation, arrest cell cycle and induce K562 towards apoptosis to achieve the goals of reversing cancer cells which could become a potential leukemia therapeutic agent in the future.

Keywords

References

  1. Ahn MY, Kang DO, Na YJ, et al (2012). Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing. Cancer Lett, 325, 189-99. https://doi.org/10.1016/j.canlet.2012.06.017
  2. Andersson LC, Nilsson K, Gahmberg CG (1979). K562--A human erythrolekemic cell line. Int J Cancer, 23, 143-7. https://doi.org/10.1002/ijc.2910230202
  3. Aversanaa CD, Leporeb I, Altucci L (2012). HDAC modulation and cell death in the clinic. Exp Cell Res, 318, 1229-44. https://doi.org/10.1016/j.yexcr.2012.01.025
  4. Bhuiyan MP, Kato T, Okauchi T, et al (2006). Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases. Bioorg Med Chem, 14, 3438-46. https://doi.org/10.1016/j.bmc.2005.12.063
  5. Byrd JC, Marcucci G, Parthun MR, et al (2005). A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood, 105, 959-67.
  6. Collins SJ (1987). The HL-60 Promyelocytic Leukemia Cell Line: Proliferation, Differentiation, and Cellular Oncogene Expression. Blood, 70, 1233-44.
  7. Editorial (2009). HDAC inhibitors in leukemia: Current status and perspectives. Leukemia Res, 33, 207-8. https://doi.org/10.1016/j.leukres.2008.07.022
  8. Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK (2005). Interactive effects of HDAC in hibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia, 7, 646-57. https://doi.org/10.1593/neo.04655
  9. Furumai R, Matsuyama A, Kobashi N, et al (2002). FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res, 62, 4916-21.
  10. Gu WX, Cueto M, Jensen PR, et al (2007). Microsporins A and B: new histone deacetylase inhibitors from the marinederived fungus Microsporum cf. gypseum and the solidphase synthesis of microsporin A. Tetrahedron, 63, 6535-41. https://doi.org/10.1016/j.tet.2007.04.025
  11. Goodsell DS, Morris GM, Olson AJ (1996). Automated docking of flexible ligands: applications of AutoDock. J Mol Recognit, 9, 1-5. https://doi.org/10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6
  12. Gottlicher M, Minucci S, Zhu P, et al (2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Eur Mol Biol Org, 20, 6969-78. https://doi.org/10.1093/emboj/20.24.6969
  13. Grant C, Rahman F, Piekarz R, et al (2010). Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticanc, 10, 997-1008. https://doi.org/10.1586/era.10.88
  14. Grant,S, Chris E; Peter K (2007). Vorinostat. Nat Rev Drug Discov, 6, 21. https://doi.org/10.1038/nrd2227
  15. Huang WJ, Chen CC, Chao SW, et al (2011). Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors. Eur J Med Chem, 46, 4042-9. https://doi.org/10.1016/j.ejmech.2011.06.002
  16. Humeniuk R, Mishra PJ, Bertino JR, Banerjee D (2009). Molecular targets for epigenetic therapy of cancer. Curr Pharm Biotechnol, 10, 161-5. https://doi.org/10.2174/138920109787315123
  17. Im JY, Park H, Kang KW, et al (2008). Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and -negative human breast cancer cells. Chem Biol Interact, 172, 235-44. https://doi.org/10.1016/j.cbi.2008.01.007
  18. Islam NM, Kato T, Nishino N, et al (2010). Bicyclic peptides as potent inhibitors of histone deacetylases:Optimization of alkyl loop length. Bioorg Med Chem Lett, 20, 997-9. https://doi.org/10.1016/j.bmcl.2009.12.054
  19. Josea B, Onikib Y, Kato T, et al (2004). Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. Bioorg Med Chen Lett, 14, 5343-6. https://doi.org/10.1016/j.bmcl.2004.08.016
  20. Josea B, Okamura S, Kato T, et al (2004). Toward an HDAC6 inhibitor: synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from $\alpha$-tubulin sequence. Bioorg Med Chem, 12, 1351-6. https://doi.org/10.1016/j.bmc.2004.01.014
  21. Matsuoka H, Fujimura T, Hayashi M, et al (2007). Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression. Biochem Pharmacol, 74, 465-76. https://doi.org/10.1016/j.bcp.2007.05.002
  22. Morris GM, Goodsell DS, Halliday RS, et al (1998). Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem, 19, 1639-62. https://doi.org/10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
  23. Morris GM, Huey R, Lindstrom W, et al (2009). AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. J Comput Chem, 30, 2785-91. https://doi.org/10.1002/jcc.21256
  24. Morris GM, Huey R, Olson AJ (2008). Using AutoDock for ligand-receptor docking. Curr Prots in Bioinform, 24, 1-40.
  25. Norikazu N, Jose B, Shinta R, et al (2004). Chlamydocin– hydroxamic acid analogues as histone deacetylase inhibitors. Bioorg Med Chem, 12, 5777-84. https://doi.org/10.1016/j.bmc.2004.08.041
  26. Nishino N, Shivashimpi GM, Soni PB, et al (2008). Interaction of aliphatic cap group in inhibition of histone deacetylases by cyclic tetrapeptides. Bioorg Med Chem, 16, 437-45. https://doi.org/10.1016/j.bmc.2007.09.021
  27. Norikazu N, Yoshikawa D, Watanabe LA, et al (2004). Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand. Bioorg Med Chem Lett, 14, 2427-31. https://doi.org/10.1016/j.bmcl.2004.03.018
  28. Rosato RR, Almenara JA, Grant S (2003). The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1. Cancer Res, 63, 3637-45.
  29. Singh EK, Ravula S, Pan CM, et al (2008). Synthesis and biological evaluation of histone deacetylase inhibitors that are based on FR235222: A cyclic tetrapeptide scaffold. Bioorg Med Chem Lett, 18, 2549-54. https://doi.org/10.1016/j.bmcl.2008.03.047
  30. Sundstrom C, Nilsson K (1976). Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer, 17, 565-77. https://doi.org/10.1002/ijc.2910170504
  31. Vega RB, Matsuda K, Oh J, et al (2004). Histone Deacetylase 4 Controls Chondrocyte Hypertrophy during Skeletogenesis. Cell, 119, 555-66. https://doi.org/10.1016/j.cell.2004.10.024
  32. Walton JD (2006). HC-toxin. Phytochemistry, 67, 1406-13. https://doi.org/10.1016/j.phytochem.2006.05.033
  33. Wang Y, Wang SY, Zhang XH, et al (2007). FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70. Biochem Bioph Co, 356, 998-1003. https://doi.org/10.1016/j.bbrc.2007.03.076

Cited by

  1. A Novel Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitor Derivative, N25, Exhibiting Improved Antitumor Activity in both Human U251 and H460 Cells vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4331
  2. Elevated Serum Ferritin Levels in Patients with Hematologic Malignancies vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6099
  3. Preparation and Antitumor Activity of a Tamibarotene-Furoxan Derivative vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6343
  4. The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat vol.37, pp.6, 2017, https://doi.org/10.1002/med.21437
  5. Epigenetic modifications in chronic myeloid leukemia cells through ruxolitinib treatment vol.120, pp.3, 2018, https://doi.org/10.1002/jcb.27744